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Background
Diffuse gliomas are the most frequent and aggressive primary brain tumors in adults, and until recently, they were classified according to the 4th edition of the World Health Organization (WHO) classification published in 2007 [16] . The former classification took into account the histological subtype (astrocytic, oligodendrocytic, and oligoastrocytic) and grade, ranging from grade II to grade IV glioblastoma, which is a highly malignant invasive and angiogenic tumor. Inconstant reproducibility and interobserver variability were critical points of this classification, relying on pathological criteria only [5] . Molecular understanding of gliomagenesis was first improved with the identification of the 1p/19q codeletion, associated with an oligodendroglial phenotype and with a better prognosis [26] . This alteration appeared to be a predictive marker of response to procarbazine, CCNU, and vincristine (PCV) [2, 3] . More recently, integrated genomic analysis of gliomas has identified IDH mutation as the key alteration in gliomagenesis [20] . IDH mutation characterizes adult grade II and III gliomas as well as secondary glioblastoma [28] and is of prognostic significance. Therefore, it was an appropriate time to introduce molecular markers into the WHO classification [17] .
Updating the 4th WHO classification of tumors of the central nervous system (CNS) has yielded major changes in the group of glial tumors [18] . The updated classification stratifies the group of "diffuse astrocytic and oligodendroglial tumors" according to the occurrence of two major genetic alterations: IDH mutation and 1p/19q codeletion. It recognizes "diffuse midline glioma, H3 K27M mutant" as a new entity. In addition, according to this new classification, the diagnosis of mixed glioma, a category that was not sharply defined until recently and was subject to high interobserver discordance [1] , is strongly discouraged.
In France, since 2008, a dedicated program has been set up for more homogeneous management of de novo adult high-grade glioma with an oligodendroglial component [prise en charge des oligodendrogliomes anaplasiques (POLA network)]. The aim of the program inter alia is to provide a pathological centralized review of the cases and centralized molecular analysis.
The aim of this study was to reclassify the entire POLA cohort according to the recent update of the 4th WHO classification of CNS tumors to analyze its prognostic and discriminant values.
Materials and methods
Patients
All 1041 patients who were sent for a central pathological review because of the suspicion of diffuse high-grade gliomas with an oligodendroglial component and included into the French nation-wide POLA cohort on June 6, 2015 were included in this study. For all cases, formalin-fixed, paraffin-embedded (FFPE) tumor tissue was available for pathological and immunohistochemical analyses. In addition, frozen material was available in up to 974 cases. Initial WHO 2007 diagnosis was retained after centralized review of all cases by four national neuropathological experts. At the time of the review process, the experts were blind of 1p19q status determination, and for cases enrolled before 2010, IDH1R132H expression was also unknown.
Patients prospectively included into the POLA cohort provided their written consent for clinical data collection and genetic analysis according to national and POLA network policies.
Clinical characteristics of the cohort are summarized in Table 1 .
Pathological review according to the 2007 WHO classification and immunohistochemistry
After the initial diagnosis of high-grade glioma with an oligodendroglial component by local pathologists, cases were centrally reviewed and included in the prospective POLA cohort. In addition, automated IHC was performed on 4-µm-thick FFPE sections with an avidin-biotin-peroxidase complex on Benchmark XT (Ventana Medical System Inc, Tucson AZ, USA) using the Ventana Kit including DAB reagent to search for the expression of IDH1 R132H (Dianova, H09), P53 (DAKO, DO.7), and ATRX (SIGMA, polyclonal).
Results
Patient characteristics and pathological diagnosis
In total, 1041 cases who were addressed to a central pathological review because of the suspicion of diffuse highgrade gliomas with an oligodendroglial component and were diagnosed between September 2008 and June 2015 were included ( Table 1 ). The median follow-up period was 19.0 months (range 0.1-77.0 months). The median age at diagnosis was 50.4 years (range 17.1-84.4). Only 7 % of patients presented with an altered functional status, while 14 % had cognitive disorders at diagnosis. Half of the patients benefited from gross total resection, and the first-line treatment corresponded to the association of chemotherapy and radiotherapy for more than 65 % of patients (Table 1) . According to the 2007 WHO classification, these 1041 cases were classified as follows: anaplastic oligodendroglioma (31.6 %), anaplastic oligoastrocytoma (27.6 %), anaplastic astrocytoma (7 %), glioblastoma with an oligodendroglial component (14.9 %), and glioblastoma (18.9 %). 
Molecular data and histomolecular classification
DNA extraction, single-nucleotide polymorphism (SNP) arrays, and comparative genomic hybridization (CGH) arrays
Following the manufacturer's recommendations, tumor DNA was extracted from frozen tissue, if available, or from FFPE samples using the iPrep ChargeSwitch ® Forensic Kit. Qualification and quantification of tumor DNA were performed using a NanoVue spectrophotometer and gel electrophoresis, respectively. In 974 cases, the genomic profile and assessment of the 1p/19q codeletion status were determined as described previously [7] . When the quantity of DNA was insufficient to perform SNP or CGH arrays (n = 6), microsatellite analysis was conducted, and microsatellite analyses (LOH) of chromosomes 1p and 19q were assessed via PCR techniques described elsewhere [13] . In addition, particular attention was paid to the following alterations: chromosome 7 gain, chromosome 10 loss, PTEN deletion, and EGFR amplification.
IDH1, IDH2, and TERT mutation status
When the results of IDH1R132H immunohistochemistry were negative or unreliable, the status of IDH1 and IDH2 mutation was addressed by direct sequencing using the Sanger method and primers, as described previously [10] . TERT mutation status was also addressed in 771 cases by direct sequencing using the Sanger method and primers, as described previously [14] .
Statistical analysis
SNP and CGH array analyses were performed as described previously [12] . For all arrays, genomic imbalances were classified as loss, gain, homozygous deletion, or amplification. For correlation analysis, the Chi-square test (or Fisher's exact test) was used to compare variables when they were scored as positive or negative. Continuous variables were compared using the Mann-Whitney U test. Progression-free survival (PFS) was defined as the time from the date of surgery to recurrence or death from any cause. Overall survival (OS) was defined as the time from the date of surgery to death from any cause. The Kaplan-Meier method was used to estimate survival distributions. Logrank tests were used for univariate comparisons. Cox proportional hazards models were used for multivariate analyses and for estimating hazard ratios in survival regression models. Multivariate analysis included all variables with a p value <0.05 in univariate analyses. All statistical tests were two-sided, and the threshold for statistical significance was p = 0.05. Analyses were conducted using PASW Statistics version 20 (IBM SPSS Inc., Chicago, IL, USA).
anaplastic astrocytoma IDH wt (3.0 %), glioblastoma IDH mut (37.1 %) glioblastoma IDH wt (28.6 %), and midline glioma with the histone H3 K27M mutation (0.5 %) (Supplementary Table 3 ; Fig. 2 ).
Prognostic value of WHO classifications and grading
The median PFS and OS were 23. Fig. 3; Table 3 ). Moreover, the new WHO 2016 classification presented with high hazard ratio both for PFS and OS (Table 3) (Fig. 3b, d ) or multivariate analysis (adjusted by the age, type of surgery, and firstline treatment). In addition, no prognostic difference was observed between grade III and IV IDH wt gliomas (Fig. 3b,  d 
Discussion
In this study, we were able to reclassify all the POLA series according to the 2016 WHO classification of brain tumors. Notably, the percentage of each category of diffuse, adult high-grade gliomas recorded in this study does not reflect the normal distribution of malignant glioma subgroups because of the inclusion criteria in the POLA network, i.e., adult malignant glioma with an oligodendroglial component. Based on these results, our first observation was a switch in grading (III versus IV) with an increased frequency of glioblastoma. Although this switch was recorded for different entities, it was more frequent for the cases initially diagnosed as grade III oligoastrocytoma, because up to 50 % cases were reclassified as glioblastoma (IDH mut or IDH wt ). Our second observation was that the new updated 2016 WHO classification had a high prognostic value. Our third observation was that grading III versus IV was prognostic for neither IDH mut 1p/19q intact gliomas nor IDH wt gliomas, which brings into question the relevance of grade in these tumors. In the POLA series, more than 400 cases were previously classified according to the 2007 WHO as mixed gliomas, a diagnostic category that should be avoided according to the 2016 classification. Of note, recommendation to limit mixed glioma diagnosis was reinforced by the recent publications on glioblastoma with oligodendroglial component (GBMO), which suggested that GBMO corresponded to various and distinct molecular entities [6, 9] . We were able to reclassify these cases on the basis of molecular characteristics. Most diffuse high-grade gliomas are now stratified according to IDH mutation and 1p/19q codeletion. In the present series, IDH1R132H immunostaining was sufficient to assess the IDH status in 562 cases (94 %) showing strong IDH1R132H expression, a frequency similar to that observed previously [25] . In the remaining cases, IDH sequencing revealed IDH1 mutation in 37 cases and IDH2 mutation in 27. Loss of nuclear ATRX expression was almost mutually exclusive from 1p/19q codeletion. We observed only three cases that demonstrated both alterations, even after repeating immunostaining and CGH analysis. These cases may correspond to the extremely rare "true" mixed glioma [11] . Although most IDH mut (1p/19q-intact) gliomas exhibited loss of ATRX (249/276), we observed 27 cases in which ATRX nuclear expression was retained. This rare molecular phenotype has been reported previously [23] . Another rare molecular phenotype was represented by loss of nuclear ATRX expression in IDH wt gliomas (20 cases); among these, a histone mutation was recorded in five of the 16 cases studied. We also observed that anaplastic oligodendroglioma IDH wt and 1p/19q-codeleted are exceptional (four cases). This last result further confirmed that almost all 1p/19q-codeleted oligodendrogliomas are IDH mutants, although some exceptions exist [3] . Because CGH analysis was performed in all cases, in addition to the 1p/19q status, we had information regarding the main alterations that characterize glioblastomas, i.e., the association of chromosome arm 7p gain and 10q loss. We observed that among the 55 anaplastic astrocytomas IDH wt , 30/55 exhibited these alterations (7p gain and 10q loss). Some authors suggested that such cases should be classified as glioblastoma [23, 24, 27] . Reuss et al. reported that up to 78 % of anaplastic astrocytoma IDH wt presented with glioblastoma molecular alterations, while 9 % were diagnosed as glioblastoma H3F3A mutated in their series [21] . However, in this study, only 55 % of anaplastic astrocytoma IDH wt demonstrated glioblastoma molecular alterations, suggesting that all anaplastic IDH wt astrocytoma should not be classified as glioblastoma.
Interestingly, we found that the 2016 WHO classification was highly accurate in predicting survival, confirming the value of adding molecular characteristics. However, this classification has some limitations. We observed that We have also reported a distinct age repartition between these three main groups (Fig. 1) . Interestingly, among the groups of IDH wt gliomas and IDH mut 1p/19q intact gliomas, grade III versus IV did not impact survival in our series. The relevance of the grading prognostic impact in the context of molecular subgroups was previously questioned in a limited number of recent studies. If the impact of grading between grade II and III gliomas was already challenged by several studies [19, 27] , the current data remained more contradictory between grade III and IV gliomas [8, 22] , suggesting, in these publications, a possible remaining prognostic value of grading. However, these studies differed from ours on several points, notably regarding the diagnosis reviewing process and the patient treatments which were more homogenous in our series, since the POLA network also provided treatment recommendations. Taken together, grading from II to IV may be questioned for all IDH wt and IDH mut 1p/19q intact gliomas. This is of high importance because the definition of anaplasia in IDH wt and IDH mut 1p/19q intact gliomas relies on the mitotic index, another parameter that is not always reproducible. Thus, based on these results, we observed the occurrence of three main molecular subgroups with distinct prognoses, which may represent a new basis for inclusion criteria in neurooncological clinical trials [15] . Recent studies have emphasized the usefulness of TERT promoter mutation to stratify gliomas [14, 27] . In this study, we observed that TERT mutation has a bimodal distribution: in IDHmut gliomas, it is mainly associated with 1p19q codeletion (although some exceptions exist as shown here and by others [4, 27] ), and it is also recorded in a large number of adult IDHwt gliomas. Moreover, we observed that TERT mutation was associated with shorter PFS in the subgroup of glioblastoma IDH wt . In contrast, TERT mutation failed to stratify the anaplastic IDH wt gliomas. Whether TERT promoter mutation in association with IDH mutation is sufficient to stratify adult gliomas requires further investigation.
Conclusion
In conclusion, the POLA series reported in this study shows that the 2016 WHO classification of adult diffuse malignant gliomas provides a high prognostic value, allowing the identification of three main subgroups for future neurooncological trials. It also clarifies the limits of grading (III versus IV) in the group of IDH mut 1p/19q intact and IDH wt gliomas. 
